

114. The Fungus (New England Compounding Center)
18 snips Aug 4, 2024
A compounding pharmacy’s drive for profit leads to a catastrophic health crisis. It highlights the troubling connection between negligence and a fungal meningitis outbreak from contaminated injections. The emotional stories of affected families reveal the tragedy of prioritizing revenue over safety. Legal consequences for pharmacy executives add a layer of courtroom drama to the tragedy. Calls for increased regulatory oversight underline the urgent need for protection in healthcare. This gripping narrative raises questions about accountability and systemic failures in the industry.
AI Snips
Chapters
Transcript
Episode notes
Over-Potent Midazolam
- In 2014, an Indianapolis hospital discovered Pharmakon's midazolam was twice as strong as labeled.
- 13 infants in the NICU were affected, but miraculously survived.
Ultra-Concentrated Morphine
- Two years later, Pharmakon shipped morphine 25 times stronger than labeled, causing respiratory arrest in an infant.
- Pharmakon's CEO, Paul Elmer, tried to cover up recurring production issues.
Profit Over Safety
- Pharmakon's CEO, Paul Elmer, prioritized profit over patient safety by concealing 70 instances of mislabeled drugs.
- He was convicted and sentenced to prison.